Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (trading symbol: EYES) on March 27, 2020, with the earliest event reported on March 27, 2020. The filing addresses critical corporate governance changes and a strategic decision to cease operations.
Key Financial Metrics and Liquidity
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, or debt levels. However, it explicitly states that the Company is unable to continue receiving funding, which is the primary driver for the operational wind-down. The Company confirmed it will continue to incur expenses during the wind-down process.
Material Changes
- Leadership Change: On March 27, 2020, the Board appointed Matthew Pfeffer, a Board member and Chairman of the Audit Committee, as Acting Chief Executive Officer effective immediately.
- Operational Cessation: On March 30, 2020, the Company announced the closure of its facility and the winding down of operations due to the COVID-19 pandemic and funding constraints.
- Workforce Reduction: The Company laid off 84 of its 108 employees effective March 30, 2020. These layoffs are permanent with no expectation of recall. A small group of employees will remain to assist with the orderly wind-down.
Outlook, Risks, and Management Commentary
Management has indicated that the wind-down activity is subject to uncertainties. The Company intends to retain an adviser experienced in winding down operations to guide the Board. There is no forward-looking guidance for future revenue or product development as the Company is exiting the market. The primary risk identified is the inability to secure funding, exacerbated by the COVID-19 pandemic.
Investor Verification Checklist
- Verify the status of the Company's remaining cash reserves and ability to fund the wind-down process.
- Confirm the timeline and legal procedures for the facility closure and asset liquidation.
- Review the attached press release (Exhibit 99.1) for details on the appointment of the Acting CEO.
- Monitor subsequent filings for updates on the wind-down adviser and potential bankruptcy proceedings.